Benitec Reacquires HCV Program in Tacere Therapeutics Buyout | GenomeWeb

Just six years after a troubled Benitec Biopharma licensed its expressed RNAi hepatitis C drug program to Tacere Therapeutics, a startup founded by former Benitec executives, the two companies have agreed to merge.

Benitec announced this week that it has acquired Tacere and its HCV drug TT-034, which is expected to enter phase I/II testing in mid-2013, for just under $1.5 million in stock, which translates to roughly 102.3 million shares or about 9.5 percent of Benitec.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.